Next Article in Journal
Modulated Electro-Hyperthermia-Induced Tumor Damage Mechanisms Revealed in Cancer Models
Next Article in Special Issue
Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of KRT5, KRT20, and ERBB2 in Muscle-Invasive Bladder Cancer Treated by Adjuvant Chemotherapy
Previous Article in Journal
Anti-Fibrotic Effect of Human Wharton’s Jelly-Derived Mesenchymal Stem Cells on Skeletal Muscle Cells, Mediated by Secretion of MMP-1
Previous Article in Special Issue
Activating Telomerase TERT Promoter Mutations and Their Application for the Detection of Bladder Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 21
Issue 17
10.3390/ijms21176271
Review Report
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

Printed Edition

A printed edition of this Special Issue is available at MDPI Books....
share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Moving towards Personalized Medicine in Muscle-Invasive Bladder Cancer: Where Are We Now and Where Are We Going?

Int. J. Mol. Sci. 2020, 21(17), 6271; https://doi.org/10.3390/ijms21176271
by Juan Carlos Pardo 1,2,†, Vicenç Ruiz de Porras 2,3,†, Andrea Plaja 1,2, Cristina Carrato 4, Olatz Etxaniz 1,2, Oscar Buisan 5 and Albert Font 1,2,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2020, 21(17), 6271; https://doi.org/10.3390/ijms21176271
Submission received: 30 July 2020 / Revised: 27 August 2020 / Accepted: 28 August 2020 / Published: 29 August 2020
(This article belongs to the Special Issue Diagnostic, Prognostic and Predictive Biological Markers in Bladder Cancer – Illumination of a Vision 2.0)

Round 1

Reviewer 1 Report

P 3, LL 116-120. Please provide the correct citation for the described study detecting mutations in different HR genes (ref 18 does not apply).

P3 LL 130-134. Please provide the number of patients for ref 21.

P12 L 491 citation should be "Eur Urol 2020" (not 2019 as suggested by acceptance date of the paper).

P4 L 179 reconsider link (corrupted?); original link provided in the paper: http://cit.ligue-cancer.net:3838/apps/consensusMIBC_web/ 

P4 L 188 suggestion for amendment: "can complement or help reconsider the standard histological classifications". Squamous differentiation might be underreported.  

P 5 L 201: Ref 31 is not "recent" compared to Refs 26-28

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Reviewer 2 Report

Juan Carlos Pedro at al. make a decent effort to summarize and present the advances in MIBC. However, there were parts of the draft that were not very easy to completely follow, especially in the part "Therapeutic implications of BC molecular subtypes". For example, luminal or basal tumors respond better to cisplatin and have the longest survival? It seems that different studies show different results but it should be presented in a more clear way.

Additionally, authors should very briefly explain what are the monoclonal antibodies or cocktail drugs that other studies use as tehrapy for Bladder cancer. For example authors should mention that atezolizumab is a PDL1 antibody, whereas nivolumab and pembrolizumab are PD-1 antibodies and what MVAC stands for (which drugs are included).

Lastly, authors should label Table 1.

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Back to TopTop